View in a different locale / language
United States
Safeguarding the safety, quality, and performance of pharmaceutical products and medical devices.
Whether you are evaluating pharmaceutical manufacturing equipment (such as single-use systems), container closure systems, delivery devices, or other medical devices, Eurofins BioPharma Product Testing laboratories in Australia offer a broad range of services to support extractables and leachables testing.
Increased demand for biopharmaceutical medicines has brought with it a greater need for extractables and leachables (E&L) testing to mitigate cross-contamination risks, prevent product adulteration, ensure patient safety, and comply with regulations.
Quantifying, identifying, and evaluating the potential migration of toxic chemicals and impurities from container closure systems, manufacturing components, or delivery devices into pharmaceuticals and biologics has become a critical quality requirement.
Regulatory agencies require extractables and leachables (E&L) testing to identify any risks of product adulteration.
Whether you are evaluating pharmaceutical manufacturing equipment (such as single-use systems), container closure systems, delivery devices, or other medical devices, Eurofins BioPharma Testing offers a broad range of services to support extractables and leachables testing. With over 20 years of experience and more than 60 scientists dedicated to E&L testing, we conduct hundreds of controlled extraction studies each year, along with the associated leachables stability studies.
We offer a variety of controlled extraction techniques to generate an extractable profile that will best match the intended use of the components being evaluated.
In addition, we conduct simulated and real-time leachables studies to evaluate the presence of leachable compounds in the drug product. Our toxicologists can then evaluate the E&L data to determine the impact to patient safety. If needed, we can use our extensive experience to successfully develop and validate fully GMP-compliant methods to monitor leachables in your drug product or intermediates.
Our extractables studies include a customisable report detailing the results of the study, including instrument parameters, system suitability results, sample chromatograms, and result tables.
Our proprietary spectral database, the Eurofins Extractables Index (EEI), contains reference spectra for over 1,500 non-volatile compounds (including common plasticizers, anti-oxidants, stabilisers, elastomers, lubricants and accelerants) that we use to identify extractable compounds detected by LC/MS.
If a compound cannot be identified with the Eurofins Extractables Index, we are able to perform additional investigative testing to identify the unknown compound. Our experienced analysts and top-of-the-line instrumentation, such as LC/MS QTOFs and Orbitraps, allow us to identify nearly all unknown compounds. We offer toxicological evaluations on extractables and leachables data.
Our E&L methods have been qualified in order to ensure accurate results and meet regulatory expectations.
Our extractables studies can be designed per guidances such as USP <665>, <1663> and <1664>, as well as ISO 10993, PQRI, BPSA and BPOG documents. We design studies to meet the expectations of FDA’s CDER/ CBER/CDRH, EMEA, and other regulatory bodies.
We have established the following semi-quantitative screening methodology to analyse extraction solutions by LC/MS, GC/MS, LC/UV, ICP/MS and ICP-OES. If needed, quantitative methods can be developed for specific compounds.
1. Semi-quantitative screening for both volatile and semi-volatile organic compounds
2. Semi-quantitative screening for non-volatile organic compounds
3. Semi-quantitative analysis for metals
4. Gravimetric determination of extractables
5. TOC, FTIR and pH
Would you like to find out more about our testing solutions, or do you need tailored analytical support? Contact us today to get in touch with our experts.